Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28747451 | 0.86 | VCP (0.46) | MAPTKMT2AMEN1CYP1A2CYP2C9 | |
| SCHEMBL9935172 | 0.84 | CA12 (0.50) | APPMAPTKMT2ALMNAKDM4E | |
| SCHEMBL28668415 | 0.83 | APP (0.43) | APPMAPTKMT2AMEN1LMNA | |
| SCHEMBL852379 | 0.83 | L3MBTL1 (0.44) | MAPTKMT2AKDM4ETDP1ALDH1A1 | |
| SCHEMBL2300644 | 0.83 | ACACB (0.44) | MAPTFFAR1ALDH1A1NPC1RAB9A | |
| SCHEMBL853115 | 0.83 | GRM5 (0.38) | MAPTKMT2AMEN1CYP1A2LMNA | |
| SCHEMBL788820 | 0.83 | APP (0.49) | APPGAAFFAR1ALDH1A1OPRM1 | |
| SCHEMBL11544791 | 0.83 | ALDH1A1 (0.53) | ALDH1A1NPC1 | |
| SCHEMBL11236951 | 0.83 | LMNA (0.51) | APPMAPTKMT2AMEN1CYP1A2 | |
| SCHEMBL7950 | 0.83 | KMT2A (0.45) | MAPTKMT2AMEN1CYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114539254-A | Preparation method of polycyclic condensed indole isoquinoline compound | 内蒙古大学 | 2022-05-27 | — | — | CN | disclosed |
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| EP-2632261-B1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS INC (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-2632261-B1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-9309260-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309260-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309260-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9302998-B2 | Aryl triazole compounds with antitumoural activity | SIGMA-TAU RESEARCH SWITZERLAND S.A. (CH) | 2016-04-05 | — | — | US | disclosed |
| US-20100160385-A1 | FUNGICIDAL TRIPHENYL-SUBSTITUTED PYRIDONES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
| EP-1226108-A4 | DIARYL-ENYNES | NPS ALLELIX CORP (CA) | 2004-06-16 | — | — | EP | disclosed |
| US-6579987-B2 | Reducing an ester containing ene-yne conjugated, silane and aryl or heteroaryl functionality to an alcohol; bromination, amination, desilanation, coupling and deprotecting | NPS ALLELIX CORPORATION (CA) | 2003-06-17 | — | — | US | disclosed |
| US-20030092769-A1 | DIARYL-ENYNES | NPS ALLELIX CORPORATION (CA) | 2003-05-15 | — | — | US | disclosed |
| US-6525085-B2 | Treating neurological and neuropsychiatric disorders | NPS ALLELIX CORP. (CA) | 2003-02-25 | — | — | US | disclosed |
| US-20020169197-A1 | Diaryl-enynes | NPS ALLELIX CORP. | 2002-11-14 | — | — | US | disclosed |
| EP-1226108-A1 | DIARYL-ENYNES | NPS Allelix Corp. (CA) | 2002-07-31 | — | — | EP | disclosed |
| US-6426364-B1 | NERVOUS SYSTEM OR PSYCHOLOGICAL DISORDERS | NPS ALLELIX CORP. (CA) | 2002-07-30 | — | — | US | disclosed |
| WO-2001032602-A1 | DIARYL-ENYNES | NPS ALLELIX CORP. (CA) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | APP 4878/4885MAPT 4276/4885KMT2A 4722/4885 |
| US-20020169197-A1 | Diaryl-enynes | CBR3, CNR1, NR3C2 | APP 4065/4885MAPT 4189/4885KMT2A 3359/4885 |
| US-20030092769-A1 | DIARYL-ENYNES | CBR3, CNR1, CBR1 | APP 4068/4885MAPT 4186/4885KMT2A 3369/4885 |
| US-20100160385-A1 | FUNGICIDAL TRIPHENYL-SUBSTITUTED PYRIDONES | PNPO, TH, CYP1A1 | APP 4662/4885MAPT 3498/4885KMT2A 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.